✨ Free AI Report
Aligos Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Aligos Therapeutics, Inc.
Company Research

Aligos Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Aligos Therapeutics, Inc. scores 4/10 on the AskCyborg Cyborg Score (Mixed). Aligos is a high-risk, catalyst-driven biotech whose value depends on clinical readouts for its hepatitis B and delta programs and on securing funding to reach them. As a clinical-stage company without approved products, Aligos carries substantial development and financing risk. Pipeline progress and cash runway are the key variables.

What is Aligos Therapeutics, Inc.'s industry? Aligos Therapeutics, Inc. (aligotx.com) operates in Infectious Disease Drugs. AskCyborg classifies Aligos Therapeutics, Inc. under Infectious Disease Drugs in its company registry.

Aligos Therapeutics is a clinical-stage biopharmaceutical company developing oral antiviral and liver-disease therapies, including candidates for chronic hepatitis B and hepatitis delta. Its pipeline targets viral and...

4/ 10Mixed

Cyborg Score thesis

Aligos is a high-risk, catalyst-driven biotech whose value depends on clinical readouts for its hepatitis B and delta programs...

Read the full analyst-debate transcript →
Industry Infectious Disease Drugs
2 named competitors
1 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 26, 2026
AI-Generated Research
30+ Page Report

Get the Latest Aligos Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Aligos Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Aligos Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Aligos Therapeutics, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Aligos Therapeutics, Inc. Overview

Pro stress-test →

Aligos Therapeutics is a clinical-stage biopharmaceutical company developing oral antiviral and liver-disease therapies, including candidates for chronic hepatitis B and hepatitis delta. Its pipeline targets viral and metabolic liver conditions with significant unmet medical need.

Strategic Profile

Pro stress-test →

The company's positioning rests on combining direct-acting antiviral chemistry with immune-modulating and NASH-oriented programs, aiming for functional cure approaches. Its competitive edge depends on clinical differentiation and partnering capacity given its need for external capital.

Competitive Landscape

Pro stress-test →

Aligos competes in chronic hepatitis B and hepatitis delta drug development against larger developers. Competitive positioning depends on the differentiation of its oral antiviral and immunotherapy candidates.

Industry Context

Aligos Therapeutics, Inc. operates in Infectious Disease Drugs.

Key facts

Founded: 2018 · Headquarters: South San Francisco, US

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Aligos Therapeutics, Inc..

  • The company is pre-revenue and depends on equity financing and partnerships to fund trials, so cash runway and dilution risk are central to its financial profile.
  • Its lead programs target chronic hepatitis B and hepatitis delta, indications with large global patient populations but limited curative options, which underpins the commercial thesis if clinical data succeed.
+1 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • Current statusAligos continues to report clinical-stage progress; specific dated 2026 milestones were not verified in this quick pass.
Get alerted when Aligos Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Gilead SciencesAntiviral medicines including hepatitis B treatments→Vir BiotechnologyClinical-stage programs for chronic hepatitis delta and B→

Compare Aligos Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Aligos Therapeutics, Inc. operates in Infectious Disease Drugs. See how the rest of the sector scores on the Cyborg framework.

Browse Infectious Disease Drugs research →
NEW · MCP server

Ask your AI assistant about Aligos Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Aligos Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Aligos Therapeutics, Inc. do this quarter?”
“Is Aligos Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does Aligos Therapeutics, Inc. do?+
Aligos Therapeutics is a clinical-stage biopharmaceutical company developing oral antiviral and liver-disease therapies, including candidates for chronic hepatitis B and hepatitis delta. Its pipeline targets viral and...
What is Aligos Therapeutics, Inc.'s Cyborg Score?+
Aligos Therapeutics, Inc. has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Aligos Therapeutics, Inc.'s main competitors?+
Named competitors include Gilead Sciences, Vir Biotechnology. The full competitive landscape is in the AskCyborg report.
How can I get the full Aligos Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Aligos Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Aligos Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.